Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis

BACKGROUND: Oral miltefosine has been shown to be non-inferior to first-line, injectable meglumine antimoniate (MA) for the treatment of cutaneous leishmaniasis (CL) in children. Miltefosine may be administered via in-home caregiver Directly Observed Therapy (cDOT), while patients must travel to cli...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:PLoS Negl Trop Dis
Päätekijät: Berger, Brandon A., Cossio, Alexandra, Saravia, Nancy Gore, Castro, Maria del Mar, Prada, Sergio, Bartlett, Allison H., Pho, Mai T.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2017
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5404883/
https://ncbi.nlm.nih.gov/pubmed/28384261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pntd.0005459
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia